Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ekaterina Balash

Physician Assistant Brooklyn, NY Physician Assistant

NPI 1922572403 CMS profile 11120755

3209 Coney Island Ave, Brooklyn, NY 11235

Open in the dashboard

General payments

$6,793

252 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ekaterina Balash of Brooklyn, NY is reported in the CMS Open Payments database as having received $6,793 across 252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,946 76
2024 General $1,124 40
2023 General $1,128 33
2022 General $1,286 51
2021 General $1,309 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ekaterina Balash
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ekaterina Balash were reported at $1,946. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ekaterina Balash Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,309 $132 $37–$438 $132
2022 $1,286 $155 $48–$522 $149
2023 $1,128 $167 $52–$557 $160
2024 $1,124 $178 $55–$600 $164
2025 $1,946 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Genzyme Corporation $1,374 36 payments
  2. Merck Sharp & Dohme Corporation $770 39 payments
  3. Regeneron Healthcare Solutions, Inc. $769 21 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $654 23 payments
  5. Insmed, Inc. $399 10 payments
  6. Verona Pharma, Inc. $349 12 payments
  7. Sanofi-Aventis U.S. LLC $310 13 payments
  8. AstraZeneca Pharmaceuticals LP $262 13 payments
  9. Edwards Lifesciences Corporation $256 10 payments
  10. Amgen Inc. $188 9 payments
  11. Other $1,464 66 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,546 249 payments
  2. Education $247 3 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,260 39 payments
  2. VERQUVO $974 48 payments
  3. DUPIXENT Inflammation And Immunology $428 11 payments
  4. OFEV $412 17 payments
  5. Arikayce $399 10 payments
  6. Ohtuvayre $349 12 payments
  7. YUPELRI $289 18 payments
  8. SAPIEN 3 Ultra RESILIA $256 10 payments
  9. DUPIXENT Immunology And Inflammation $250 7 payments
  10. FARXIGA $241 12 payments
  11. Other $2,502 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record